Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -15.99% is 874% below its 4-year average of 2.07%, near the low end of its 4-year range (-15.99%–8.99%).
As of the fiscal period ended Wednesday, December 31, 2025. 133.43% below its 12-month average of -6.85%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2025 (2025-12-31): -10.82%.
RETURN ON ASSETS (ROA)
-15.99%
RETURN ON ASSETS (ROA) AVG TTM
-6.85%
RETURN ON ASSETS (ROA) AVG 3Y
0.40%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-133.43%
CURRENT VS 3Y AVG
-4148.10%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+50.44%
vs the sector median at left
Zhengye Biotechnology Holding Limited
Market Cap
$52.60M
Return on Assets (ROA)
-15.99%
TTM Avg
-6.85%
3Y Avg
0.40%
5Y Avg
N/A
Market Cap
$52.83M
Return on Assets (ROA)
-54.01%
TTM Avg
-81.00%
3Y Avg
-93.15%
5Y Avg
-65.68%
Market Cap
$51.99M
Return on Assets (ROA)
N/A
TTM Avg
-109.69%
3Y Avg
-346.56%
5Y Avg
-277.44%
Market Cap
$51.88M
Return on Assets (ROA)
-34.52%
TTM Avg
-27.74%
3Y Avg
-32.72%
5Y Avg
-28.49%
Market Cap
$53.70M
Return on Assets (ROA)
-32404.78%
TTM Avg
-23.59%
3Y Avg
-11.80%
5Y Avg
-9.44%
Market Cap
$51.23M
Return on Assets (ROA)
-127.67%
TTM Avg
-99.17%
3Y Avg
-76.90%
5Y Avg
-71.83%
Market Cap
$51.19M
Return on Assets (ROA)
-53.31%
TTM Avg
-34.34%
3Y Avg
-114.79%
5Y Avg
-190.75%
Market Cap
$51.12M
Return on Assets (ROA)
-44.77%
TTM Avg
-25.55%
3Y Avg
-81.14%
5Y Avg
-76.43%
Market Cap
$54.14M
Return on Assets (ROA)
-49.54%
TTM Avg
-66.28%
3Y Avg
-54.88%
5Y Avg
-41.21%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Limited (ZYBT) | $52.60M | -15.99% | -6.85% | 0.40% | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | -54.01% | -81.00% | -93.15% | -65.68% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | -109.69% | -346.56% | -277.44% |
| ImageneBio Inc (IMA)vs › | $51.88M | -34.52% | -27.74% | -32.72% | -28.49% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | -32404.78% | -23.59% | -11.80% | -9.44% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | -127.67% | -99.17% | -76.90% | -71.83% |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | -53.31% | -34.34% | -114.79% | -190.75% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | -44.77% | -25.55% | -81.14% | -76.43% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | -49.54% | -66.28% | -54.88% | -41.21% |
| biote Corp. (BTMD)vs › | $50.28M | 5.76% | 13.86% | 7.25% | 29.75% |
ROA
-16.0%
ROE
-27.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -15.99% |
| 2024-12-31 | 2.29% |
| 2023-12-31 | 6.29% |
| 2022-12-31 | 8.99% |
| 2021-12-31 | 8.75% |
